Metastatic colorectal cancer
Clinical trial safety: RAISE
Adverse reaction profile for CYRAMZA + FOLFIRI1,2
Adverse reactions occurring at incidence rate ≥5% and a ≥2% difference between arms in patients receiving CYRAMZA1
SELECT IMPORTANT SAFETY INFORMATION
- The most common serious adverse reactions with CYRAMZA plus FOLFIRI were diarrhea (3.6%), intestinal obstruction (3.0%), and febrile neutropenia (2.8%).
- Treatment discontinuation of any study drug due to adverse reactions occurred more frequently in CYRAMZA plus FOLFIRI-treated patients (29%) than in placebo plus FOLFIRI-treated patients (13%). The most common adverse reactions leading to discontinuation of any component of CYRAMZA plus FOLFIRI as compared to placebo plus FOLFIRI were neutropenia (12.5% versus 5.3%) and thrombocytopenia (4.2% versus 0.8%). The most common adverse reactions leading to treatment discontinuation of CYRAMZA were proteinuria (1.5%) and gastrointestinal perforation (1.7%).
- Clinically relevant adverse reactions reported in ≥1% and <5% of CYRAMZA plus FOLFIRI-treated patients in RAISE consisted of gastrointestinal perforation (1.7%), including 4 fatal events.